Whetstone Capital Advisors LLC Has $13.06 Million Holdings in OptimizeRx Corp. $OPRX

Key Points

• Whetstone Capital Advisors LLC increased its holdings in OptimizeRx Corp. by 11.7% in Q1, now owning 1,508,303 shares valued at approximately $13.06 million.
• Several institutional investors, including JPMorgan Chase & Co., have significantly increased their stakes in OptimizeRx, reflecting growing interest; 76.47% of the stock is held by institutional investors.
• OptimizeRx has received multiple buy ratings from brokerages, with a consensus target price of $11.81 and an overall consensus rating of "Moderate Buy."

Whetstone Capital Advisors LLC boosted its position in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) by 11.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,508,303 shares of the company's stock after buying an additional 157,880 shares during the quarter. OptimizeRx makes up about 5.8% of Whetstone Capital Advisors LLC's holdings, making the stock its 6th largest position. Whetstone Capital Advisors LLC owned about 8.16% of OptimizeRx worth $13,062,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of OPRX. Invesco Ltd. purchased a new position in shares of OptimizeRx in the first quarter valued at $2,542,000. Tang Capital Management LLC purchased a new position in shares of OptimizeRx in the fourth quarter valued at $1,075,000. Walleye Capital LLC purchased a new position in shares of OptimizeRx in the fourth quarter valued at $673,000. Marshall Wace LLP purchased a new position in shares of OptimizeRx in the fourth quarter valued at $653,000. Finally, Manatuck Hill Partners LLC purchased a new position in shares of OptimizeRx in the fourth quarter valued at $486,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Price Performance

OPRX stock traded up $0.40 during mid-day trading on Tuesday, hitting $17.40. 80,416 shares of the stock were exchanged, compared to its average volume of 380,380. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The business has a fifty day moving average price of $14.04 and a 200 day moving average price of $10.74. OptimizeRx Corp. has a 12 month low of $3.78 and a 12 month high of $18.22. The stock has a market capitalization of $323.12 million, a price-to-earnings ratio of -32.22, a PEG ratio of 2.44 and a beta of 1.33.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on OPRX shares. Roth Capital reiterated a "buy" rating on shares of OptimizeRx in a research report on Friday, August 8th. JMP Securities lifted their price target on OptimizeRx from $14.00 to $20.00 and gave the company a "market outperform" rating in a research report on Monday, August 11th. Stifel Nicolaus lifted their price target on OptimizeRx from $16.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, August 8th. B. Riley restated a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Finally, Wall Street Zen upgraded OptimizeRx from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $11.81.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.